This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Durata Therapeutics Announces Five Abstracts Concerning Dalbavancin And Management Of AbSSTI At ICAAC 2012

Durata Therapeutics (NASDAQ: DRTX) today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The conference will be held in San Francisco, CA from September 9-12, 2012.

Sunday, September 9, 2012

  • Update of Dalbavancin (DAL) Activity in the USA: Report from the SENTRY Program (2011). (Jones, et al). Session Number: 010, Presentation Number: C2-138, 11:30 AM – 1:30 PM (Halls A-C)
  • Comparative In Vitro Activity of Dalbavancin (DAL) and Other Gram- Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134, 11:30 – 1:30 PM (Halls A-C).
  • Costs of Outpatient Parenteral Antibiotic Therapy (OPAT) for the Management of Gram+ Acute Bacterial Skin and Soft Tissue Infections (abSSTIs) (Khachatryan, et al). Session Number: 020, Presentation Number: K-239, 11:30 AM – 1:30 PM (Halls A-C)

Monday, September 10, 2012

  • A Single-Center, Randomized, Placebo- and Positive-Controlled, Parallel-Group Study of the Electrocardiographic Effects of Dalbavancin in Healthy Male and Female Subjects. (Dunne, et al). Session Number: 082, Presentation Number: A-623, 11:15 AM – 1:15 PM (Halls A-C)

Tuesday, September 11, 2012

  • A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Dalbavancin Using Fastidious and non-Fastidious Gram-Positive Organisms (Killian, et al). Session Number: 173, Presentation Number: E-1467, 11:15 AM- 1:15 PM (Halls A-C)

*Note: all times are listed in Pacific Time.

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI, caused by Gram-positive bacteria, such as S. aureus, including Methicillin-Resistant and multi-drug resistant strains, and certain streptococcal species. The product candidate is a semi-synthetic lipoglycopeptide designed and under investigation for once-weekly intravenous dosing which may facilitate the treatment of patients with abSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient’s hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs